...
首页> 外文期刊>Breast cancer research and treatment. >Breast cancers found by screening: earlier detection, lower malignant potential or both?
【24h】

Breast cancers found by screening: earlier detection, lower malignant potential or both?

机译:通过筛查发现的乳腺癌:较早发现,较低的恶性潜能或两者兼有?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A population-based study was performed to compare the characteristics of clinically detected breast cancers and cancers detected by the Dutch screening program. To determine whether differences are most likely to be explained by earlier diagnosis or by the detection of biologically different cancers in the screening program, comparisons were stratified according to tumor size. Data were obtained from the population-based Eindhoven Cancer Registry. During the period 1996-1999, 568 screen-detected and 630 clinically detected invasive breast cancers were available for analysis. Compared with patients with clinically detected breast cancer, women with screen-detected breast cancer had smaller tumors (P < 0.0001), were more likely to have negative lymph nodes (P < 0.0001), tumors with a positive estrogen (P = 0.007) or progesterone (P = 0.019) receptor status and a lower mitotic activity index (P = 0.009). In the group with cancers < or = 1.0 cm the screen-detected were more likely to have negative estrogen receptors (P = 0.027). The group with screen-detected tumors 1.1-2.0 cm across were more likely to have positive estrogen and progesterone receptors (P = 0.005 and P = 0.044, respectively) and tended to have a lower mitotic activity index (P = 0.078). No significant differences were found between screen-detected and clinically detected breast cancers of 2.1-3.0 cm across. After adjustments for tumor size, most of the differences between clinically detected and screen-detected breast cancers disappeared, suggesting that screen-detected breast cancers represent tumors in an earlier phase of their development, not a biologically different class.
机译:进行了一项基于人群的研究,以比较临床检测到的乳腺癌和荷兰筛查程序检测到的癌症的特征。为了确定是否最有可能通过早期诊断或通过在筛查程序中检测生物学上不同的癌症来解释差异,根据肿瘤大小对比较进行分层。数据从基于人群的埃因霍温癌症登记处获得。在1996年至1999年期间,有568例经筛查和630例临床检测为浸润性乳腺癌可供分析。与经临床检测的乳腺癌患者相比,经筛查的乳腺癌女性肿瘤较小(P <0.0001),淋巴结阴性(P <0.0001),雌激素阳性(P = 0.007)或孕酮(P = 0.019)受体状态和较低的有丝分裂活性指数(P = 0.009)。在癌症<或= 1.0 cm的组中,经筛查发现的雌激素受体阴性可能性更高(P = 0.027)。筛查发现的肿瘤长1.1-2.0 cm的组更可能具有阳性的雌激素和孕激素受体(分别为P = 0.005和P = 0.044),并且有丝分裂活性指数较低(P = 0.078)。在筛查到的和临床检测到的2.1-3.0 cm的乳腺癌之间没有发现显着差异。调整肿瘤大小后,临床检测到的乳腺癌与筛查的乳腺癌之间的大多数差异消失了,这表明筛查的乳腺癌代表的是肿瘤发展的早期阶段,而不是生物学上不同的类别。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号